AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Syndax Pharmaceuticals Inc (NASDAQ:SNDX)
12.98 USD
-0.580 4.277%Sponsored Reports
Loading...
| Previous Close (in USD) | 13.56 |
|---|---|
| Change | -0.580 4.277% |
| 52 W H/L (in USD) | 25.340/11.215 |
| EBITDA (in USD) | -263.441M |
| PE Ratio | -- |
| Volume | 400121 |
| Diluted Eps TTM | -3.24 |
| Total Assets (in USD) | 612.88M |
|---|---|
| Total Liabilities (in USD) | 58.684M |
| Revenue TTM (in USD) | 126.576M |
| Cash (in USD) | 295.394M |
| Market Cap (in USD) | 1,713.340 M |
| Revenue Per Share TTM | 2.173 |
| Gross Profit TTM (in USD) | 139.709M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
Employees: 184
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Michael A. Metzger M.B.A. | CEO & Director | 1971 |
| 2. | Dr. Briggs W. Morrison M.D. | Pres, Head of R&D and Director | 1960 |
| 3. | Dr. Anjali Ganguli Ph.D. | Chief Bus. Officer | 1976 |
| 4. | Dr. Peter Ordentlich B.Sc., Ph.D. | Co-Founder & Chief Scientific Officer | 1969 |
| 5. | Dr. Richard A. Heyman Ph.D. | Co-Founder | 1957 |
| 6. | Dr. Ronald M. Evans Ph.D. | Co-Founder, Advisor and Chair of Scientific Advisory Board | NA |
| 7. | Dr. Michael Downes Ph.D. | Co-Founder | NA |
| 8. | Mr. Keith Alan Goldan CPA | Chief Financial Officer | 1971 |
| 9. | Mr. Alexander Nolte | VP & Chief Accounting Officer | 1973 |
| 10. | Sharon Klahre | VP of Investor Relations & Communications | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.720 1.026% | 70.17 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.980 1.404% | 68.8 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-7.590 1.510% | 504.79 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+3.800 0.598% | 638.01 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -149.338M | 24.926M | -73.158M | -56.047M | -73.961M |
| Minority Interest | - | - | - | - | - |
| Net Income | -143.749M | 24.926M | -73.069M | -55.955M | -73.961M |
| Selling General Administrative | 33.258M | 25.241M | 22.505M | 16.062M | 17.287M |
| Gross Profit | - | 139.709M | 1.517M | 1.517M | 1.517M |
| Reconciled Depreciation | 0.033M | 0.043M | 0.089M | 0.092M | 0.078M |
| Ebit | -151.79M | 26.177M | -71.512M | -57.631M | -75.954M |
| Ebitda | -151.757M | 26.22M | -71.423M | -57.539M | -75.876M |
| Depreciation And Amortization | 0.033M | 0.043M | 0.089M | 0.092M | 0.078M |
| Operating Income | -151.757M | 26.22M | -71.423M | -57.539M | -75.876M |
| Other Operating Expenses | 151.757M | 113.489M | 72.94M | 59.056M | 77.393M |
| Interest Expense | 3.137M | 1.899M | 2.357M | 1.571M | 1.942M |
| Tax Provision | - | - | - | - | - |
| Interest Income | 5.872M | 0.403M | 0.841M | 1.571M | 1.942M |
| Net Interest Income | 2.735M | -1.496M | -1.516M | 1.571M | 1.942M |
| Income Tax Expense | -5.589M | -0.043M | -0.089M | -0.092M | 1.915M |
| Total Revenue | 0M | 139.709M | 1.517M | 1.517M | 1.517M |
| Total Operating Expenses | 151.757M | 113.489M | 72.94M | 59.056M | 77.393M |
| Cost Of Revenue | - | - | - | - | 0M |
| Total Other Income Expense Net | 2.419M | -1.294M | -1.735M | 1.492M | 1.915M |
| Net Income From Continuing Ops | -149.338M | 24.926M | -73.158M | -56.047M | -73.961M |
| Net Income Applicable To Common Shares | -149.338M | 24.926M | -77.064M | -56.047M | -73.961M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 612.88M | 497.236M | 449.657M | 300.613M | 63.525M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 0.063M | 0.194M | 0.38M | 0.341M | 0.763M |
| Total Liab | 58.684M | 29.787M | 41.289M | 48.425M | 31.925M |
| Total Stockholder Equity | 554.196M | 467.449M | 408.368M | 252.188M | 31.6M |
| Other Current Liab | 0.888M | 24.276M | 1.889M | 11.246M | 10.195M |
| Common Stock | 0.008M | 0.007M | 0.006M | 0.005M | 0.003M |
| Capital Stock | 0.008M | 0.007M | 0.006M | 0.005M | 0.003M |
| Retained Earnings | -902.4M | -693.04M | -543.702M | -568.628M | -495.47M |
| Good Will | - | - | - | - | - |
| Other Assets | - | 0.922M | 449.657M | 1.557M | 0.197M |
| Cash | 295.394M | 74.356M | 221.965M | 115.243M | 24.609M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 58.096M | 29.065M | 20.683M | 18.872M | 18.368M |
| Current Deferred Revenue | 38.968M | - | 12.764M | 1.517M | 1.517M |
| Net Debt | -293.759M | -73.195M | -200.998M | -94.707M | -23.712M |
| Short Term Debt | 1.047M | 0.439M | 0.361M | 2.601M | 0.478M |
| Short Long Term Debt | - | - | - | 2.285M | - |
| Short Long Term Debt Total | 1.635M | 1.161M | 20.967M | 20.536M | 0.897M |
| Other Stockholder Equity | 1456.37M | 1161.288M | 952.019M | 820.815M | 527.067M |
| Property Plant Equipment | - | 1.059M | 0.278M | 0.192M | 0.997M |
| Total Current Assets | 580.876M | 481.271M | 448.396M | 298.864M | 62.331M |
| Long Term Investments | 29.829M | 5.469M | - | - | - |
| Short Term Investments | 282.189M | 410.041M | 217.971M | 177.822M | 35.166M |
| Net Receivables | 1.227M | 4.057M | 0.429M | 0.175M | 0.116M |
| Long Term Debt | - | - | 19.895M | 17.834M | - |
| Inventory | 2.003M | -4.251M | 7.651M | 5.283M | 1.677M |
| Accounts Payable | 17.193M | 4.35M | 5.669M | 3.508M | 6.178M |
| Accumulated Other Comprehensive Income | 0.218M | -0.806M | 0.045M | -0.004M | -0.31M |
| Non Currrent Assets Other | 0.68M | 9.437M | 0.983M | 1.267M | 0.197M |
| Non Current Assets Total | 32.004M | 15.965M | 1.261M | 1.749M | 1.194M |
| Capital Lease Obligations | 1.635M | 1.161M | 1.072M | 0.417M | 0.897M |
| Long Term Debt Total | - | - | 19.895M | 17.834M | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -186.188M | -40.744M | -142.53M | 12.781M | 51.585M |
| Total Cashflows From Investing Activities | -186.188M | -40.873M | -142.53M | 12.781M | 51.398M |
| Total Cash From Financing Activities | 172.254M | 118.464M | 304.424M | 28.57M | 15.729M |
| Net Income | -149.338M | 24.926M | -73.158M | -56.047M | -73.961M |
| Change In Cash | -147.609M | 106.722M | 90.634M | -9.261M | -1.404M |
| Begin Period Cash Flow | 222.08M | 115.358M | 24.724M | 33.985M | 35.389M |
| End Period Cash Flow | 74.471M | 222.08M | 115.358M | 24.724M | 33.985M |
| Total Cash From Operating Activities | -133.675M | 29.131M | -71.26M | -50.612M | -68.531M |
| Depreciation | 0.033M | 0.043M | 0.089M | 0.092M | 0.078M |
| Other Cashflows From Investing Activities | - | - | - | 12.781M | 51.585M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | - | - | - |
| Sale Purchase Of Stock | - | 24.848M | 284.693M | 28.57M | 15.721M |
| Other Cashflows From Financing Activities | 11.459M | 7.279M | 26.709M | 0.36M | 0.232M |
| Capital Expenditures | 0M | 0.129M | 0.129M | 0.129M | 0.187M |
| Change In Working Capital | 1.656M | -9.597M | -7.934M | -0.241M | -0.302M |
| Other Non Cash Items | -2.045M | 0.187M | 0.816M | 0.359M | 0.011M |
| Free Cash Flow | -133.675M | 29.002M | -71.26M | -50.612M | -68.718M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Health Care Inv | 11 months ago | 4249352 |
| 2. | SPDR® S&P Biotech ETF | 11 months ago | 2897990 |
| 3. | Vanguard Total Stock Mkt Idx Inv | 11 months ago | 2729149 |
| 4. | iShares Russell 2000 ETF | 11 months ago | 1826515 |
| 5. | Vanguard Institutional Extnd Mkt Idx Tr | 11 months ago | 1266442 |
| 6. | Fidelity Small Cap Index | 1 year ago | 682428 |
| 7. | Wellington Global Hlthcr Eq USD G Ac | 11 months ago | 664401 |
| 8. | Belfius Equities Cure C Cap | 11 months ago | 630000 |
| 9. | Candriam Global Equities Oncology | 11 months ago | 630000 |
| 10. | Franklin Biotechnology Discv A(acc)USD | 11 months ago | 628009 |
| 11. | T. Rowe Price Small-Cap Value | 11 months ago | 607500 |
| 12. | iShares Biotechnology ETF | 11 months ago | 595153 |
| 13. | Biotech Growth Ord | 1 year ago | 584600 |
| 14. | Franklin Small Cap Growth Adv | 11 months ago | 572400 |
| 15. | iShares Russell 2000 Growth ETF | 11 months ago | 557783 |
| 16. | Franklin US Small Cap Growth Equity | 11 months ago | 500100 |
| 17. | Franklin Small Cap Growth SMA | 11 months ago | 500100 |
| 18. | T. Rowe Price US Small-Cap Core Equity | 11 months ago | 494654 |
| 19. | T. Rowe Price Small-Cap Stock | 11 months ago | 494654 |
| 20. | State St Russell Sm/Mid Cp® Indx NL Cl C | 11 months ago | 480536 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Wellington Management Company LLP | 1 year ago | 7585221 |
| 2. | BlackRock Inc | 1 year ago | 7015548 |
| 3. | Kynam Capital Management, LP | 11 months ago | 5660000 |
| 4. | State Street Corporation | 1 year ago | 5016224 |
| 5. | Vanguard Group Inc | 11 months ago | 4926984 |
| 6. | venBio Select Advisor LLC | 11 months ago | 4222222 |
| 7. | Eversept Partners, LLC | 1 year ago | 3383244 |
| 8. | Goldman Sachs Group Inc | 1 year ago | 2501896 |
| 9. | T. Rowe Price Investment Management,Inc. | 11 months ago | 2459235 |
| 10. | Avidity Partners Management LP | 11 months ago | 2412500 |
| 11. | Marshall Wace Asset Management Ltd | 11 months ago | 2032059 |
| 12. | Bvf Inc | 11 months ago | 1875000 |
| 13. | Orbimed Advisors, LLC | 11 months ago | 1749000 |
| 14. | Morgan Stanley - Brokerage Accounts | 1 year ago | 1664306 |
| 15. | Sofinnova Ventures | 11 months ago | 1608540 |
| 16. | Woodline Partners LP | 11 months ago | 1544287 |
| 17. | Geode Capital Management, LLC | 1 year ago | 1535055 |
| 18. | Franklin Resources Inc | 1 year ago | 1352905 |
| 19. | StemPoint Capital LP | 11 months ago | 1100988 |
| 20. | Candriam Luxembourg S.C.A. | 11 months ago | 1045032 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Related Articles
Loading...
